Background
==========

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder with axonal degeneration affecting the Central Nervous system, which shows three major evolutive phenotypes: relapsing-remitting, primary progressive and secondary progressive. The etiology of MS is unknown, but it is probably multifactorial, with an interplay of genetic, ethnic, geographical and environmental factors (infectious or chemical) \[[@B1]-[@B5]\]. It has been proposed that MS is an autoimmune disorder with susceptibility influenced, if not determined, by a relatively small number of genes \[[@B1]\]. Findings from studies on seasonality in MS patients' birth, disease onset and exacerbations, as well as apparent temporal trends in incidence and gender ratio support an influential effect of viruses, metabolic and lifestyle factors on MS risk. Epstein-Barr virus, vitamin D status, and smoking are factors that may explain such epidemiological patterns \[[@B4]\].

A haplotype within the major histocompatibility region is the major risk factor for MS. But despite clear evidence for a genetic component additional risk, specific gene variants were not identified until the recent advent of genome-wide association studies (GWAS). Until 2010, 11 GWAS have been conducted on MS, and, together with follow-up studies, these GWAS have confirmed 16 loci with genome-wide significance \[[@B6],[@B7]\]. Many of these common risk variants are located at, or near to, genes with central immunological functions (such as interleukin 2 and 7 receptors, CD58, CD6, CD40, TNFRSF1A and others) and the majority are associated with other autoimmune diseases \[[@B6],[@B7]\]. A further report of the International Multiple Sclerosis Genetics Consortium identified at least 50 loci related with the risk for MS \[[@B8]\].

Although the underlying molecular mechanisms for the axonal degeneration are unknown, the degree of inflammatory demyelination correlates with the extent of axonal damage. This suggests an involvement of the proinflammatory mediators in inducing axonal degeneration \[[@B9]\]. However, the alternative possibility that axonal regeneration should be severely impaired in MS lesions could be suggested, since an accumulation of glial scar and neurite growth inhibitors provide a non-permissive environment for re-growth of damaged axons \[[@B10]\].

LINGO1 (leucine rich repeat and Ig domain containing Nogo receptor interacting protein-1) has a possible role in the pathogenesis of MS. LINGO1 is a transmembrane protein expressed in neural cells which inhibits the differentiation of oligodendrocyte precursor cells into mature oligodendrocytes, as well as myelination and remyelination \[[@B11],[@B12]\]. LINGO1 comprises 12 leucine rich repeats followed by an immunoglobulin (Ig) domain and a short cytoplasmic tail. It is encoded by the *LINGO1* gene (OMIM 609791, Gene Identity 84894) located in the chromosome 15q24.3 \[[@B13],[@B14]\]. In neurons, LINGO1 simultaneously interacts with the Nogo-66 receptor (NgR) and p75^NTR^ or TROY to form a receptor complex that binds the structurally diverse associated glycoprotein and oligodendrocyte myelin glycoprotein, resulting in the restriction of axonal elongation via activation of the small GTPase RhoA \[[@B14]-[@B16]\]. Two *LINGO1* variants designated as rs9652490 and rs11856808 have been claimed to be associated in case--control GWAS with other neurological conditions such as essential tremor \[[@B17],[@B18]\] and Parkinson's disease \[[@B18],[@B19]\]. Further studies confirmed the association with essential tremor, but discarded a major association with Parkinson's disease \[[@B20]-[@B24]\]. These single nucleotide polymorphisms (SNPs) are, according to HapMap, tag-SNPs for the following SNPs located within the *LINGO1* gene: rs907400, rs8029432, rs1877294, rs7165679, rs9920101 and rs9920127, as well as nine additional SNPs in the 3' flanking region of the gene. Figure [1](#F1){ref-type="fig"} shows that the linkage between the two SNPs analyzed in this study and the six SNPs located within the gene differ, depending on ethnicity.

![**Scheme and linkage analysis of the SNPs analyzed in this study.** The linkage figure was composed with Haploview Ver. 3, release R-2, excluding individuals with \> 50% missing genotypes, according to the standard colour scheme (D'/LOD), and the D' values (×100) are shown when relevant. Top: The area covers the whole LINGO1 gene as well as the 3' flanking region. The SNPs tested are marked at the right side of the figure. These data correspond to Caucasian individuals (Utah residents with ancestry from northern and western Europe). Bottom: Linkage figures focusing on the two SNPs tested and six SNPs located within the LINGO1 gene. The populations correspond to: CEU, Utah residents with ancestry from northern and western Europe; ASW, African ancestry in Southwest USA; JPT, Japanese in Tokyo, Japan; CHB, Han Chinese in Beijing, China; MXL, Mexican ancestry in Los Angeles, California; TSI, Tuscany in Italia. (see the website <http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html>).](1471-2377-13-34-1){#F1}

In an attempt to identify additional factors involved in MS susceptibility, we genotyped the SNPs rs9652490 and rs11856808 in the *LINGO1* gene, in patients with MS and in healthy subjects. Although *LINGO1* polymorphisms were not significantly associated with the risk and hence are not mentioned among the possible susceptibility genes in GWAS studies, the possible role of LINGO1 in the pathogenesis of MS suggests that the *LINGO1* gene should be a candidate gene for modifying MS risk.

Methods
=======

Patients and controls
---------------------

We recruited 293 unrelated Caucasian Spanish patients who fulfilled McDonald's criteria for definite MS \[[@B25]\], with no other previous neurological diseases. Recruiting sources were the following: the "Multiple Sclerosis Association of Madrid"; n = 165 cases), the Health Areas of the Hospital La-Mancha-Centro (Alcázar de San Juan, Ciudad Real; n = 65 cases), and University Hospitals "Doce de Octubre" (Madrid, n = 32 cases), and "Príncipe de Asturias" (Alcalá de Henares, Madrid; n = 31 cases). The control group was composed of 318 healthy unrelated Caucasian Spanish individuals gender and age-matched with the patients (97 men, 221 women; mean age 43.76 ± 12.4 years). These patients participated in previous genetic studies \[[@B26]-[@B28]\]. The control individuals were students or professors from the University of Extremadura, Badajoz, Spain (n = 150), and the healthy spouses of patients with neurological disorders who came from different regions of Spain to the Department of Neurology, Clínica Universitaria de Navarra, University of Navarra School of Medicine, Pamplona, Spain (n = 168). All the participants were included in the study after giving written informed consent. Table [1](#T1){ref-type="table"} summarizes the characteristics of the individuals included in the study. The protocol was approved by the Ethics Committees of the University Hospitals "Príncipe de Asturias" and "Infanta Cristina" (Badajoz) and collaborating centres. The study was conducted according to the principles expressed in the declaration of Helsinki.

###### 

Characteristics of the individuals included in the study

                                         **Overall MS patients**   **RRMS**      **SPMS**      **PPMS**      **Control individuals**
  -------------------------------------- ------------------------- ------------- ------------- ------------- -------------------------
  Gender (females/males)                 203/90                    115/44        59/32         29/14         221/97
  Age (mean ± SD)                        43.9 ± 11.4               40.0 ± 10.5   47.2 ± 9.9    54.4 ± 10.2   43.7 ± 12.4
  Age at onset (mean ± SD)               32.8 ± 10.9               29.5 ± 8.5    34.9 ± 11.8   43.4 ± 11.6   \--
  Disease duration (mean ± SD)           11.1 ± 7.9                10.5 ± 8.2    12.3 ± 9.3    11.0 ± 7.7    \--
  Expanded disability status scale       4.7 ± 2.2                 2.9 ± 1.5     6.0 ± 1.3     6.8 ± 0.9     \--
  Progression index (EDSS/MS duration)   0.5 ± 0.4                 0.3 ± 0.2     0.6 ± 0.5     0.7 ± 0.4     \--

Genotyping of *LINGO1* rs9652490 and rs18856808 polymorphisms
-------------------------------------------------------------

Genomic DNA was obtained from peripheral leukocytes and purified according to standard procedures. Two polymorphisms of *LINGO1* gene, rs9652490 A/G and rs11856808 C/T, were genotyped using KASPar assays according to the manufacturer's protocol (<http://www.kbioscience.co.uk>). PCR was performed on a 96-well Tetrad 2 Peltier Thermal Cycler (BIO-RAD, Hercules, CA). PCR KASPar's protocol was performed as following: a denaturation step of 10 min, twenty--eight cycles of 15 sec denaturing at 94°C, annealing of 20 sec at 57°C, and extension of 30 sec at 72°C. PCR were followed by a final extension step of 5 min at 72°C. Genotype calling was performed in an allelic discrimination analysis module of the 7300 High Throughput Sequence Detection System (ABI Sequence Detection Software v.1.2.3, Applied Biosystems, Foster City, CA, USA). We sequenced the SNP region in several individuals for each genotype for quality control of genotyping. Genotype success rate was 96.8%.

Statistical analysis
--------------------

Hardy-Weinberg equilibrium (HWE) was analyzed by the DeFinetti software (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). Allelic and genotype frequency analysis was performed with PLINK v.1.07 software (Shaun Purcell; <http://pngu.mgh.harvard.edu/purcell/plink/>). We performed Westfall and Young's step-down max (T) permutation procedure implemented in PLINK v.1.07 by running 100.000 permutations to correct for multiple testing \[[@B29]\]. Level of statistical significance was considered at corrected p-values ≤ 0.05. The linkage disequilibrium between the two polymorphisms was calculated with Haploview Ver. 3. For categorical variables the intergroup comparison values were calculated by using the chi-square or Fisher\'s exact tests when appropriate. For continuous variables, the Kolmogorov-Smirnoff test was used to analyze normality in the distribution. Then, the Student two sample *t* test was used for variables that followed a normal distribution (age and age at onset), and the Mann--Whitney test was used for the duration of disease and the severity scores expanded disability status scale and progression index, because no normal distribution was observed for this parameter.The 95% confidence intervals were also calculated. The statistical power was calculated for the sample size of this study (this was determined from allele frequencies with a genetic model analyzing the frequency for carriers of the disease gene with OR = 1.5; p = 0.05) \[[@B30]\]. Bilateral and unilateral associations of the risk with the variant allele are as follows rs9652490 G = 80.1% and 87.7% and rs11856808 T = 91.9% and 96.7%, respectively. Haplotype reconstruction was performed using the program PHASE v2.1.1 \[[@B31]\]. We used the default model for recombination rate variation with 1000 iterations, 500 burn-in iterations and a thinning interval of 1 as described elsewhere \[[@B32]\].

Results
=======

The frequencies of *LINGO1* rs9652490 and rs11856808 genotypes and alleles in patients with MS did not differ from those of controls (Table [2](#T2){ref-type="table"}). The genotype and allele frequencies in MS patients and healthy subjects were in Hardy-Weinberg's equilibrium. Both SNPs were in linkage disequilibrium with LOD values equal to 48.67 and 36.17 among patients and controls subjects, respectively (r-squared = 0.46 and 0.48, respectively). Mean age at onset of MS did not differ significantly between patients carrying *LINGO1* rs9652490 A/A (mean ± SD = 33.0 ± 11.5 years), A/G (mean ± SD = 32.4 ± 9.8 years) and G/G (mean ± SD = 38.5 ± 24.7 years); (p = 0.818 for the comparison of carriers vs. non-carriers of variant alleles), and between patients with genotypes *LINGO1* rs11856808 C/C (mean ± SD = 32.5 ± 11.5 years), C/T (mean ± SD = 32.6 ± 10,6 years) and T/T (mean ± SD = 35.6 ± 10.9 years); (p = 0.835 for the comparison of carriers vs. non-carriers of variant alleles).

###### 

***LINGO1*genotype and allelic variants of patients with multiple sclerosis (MS) and healthy volunteers**

                             **MS PATIENTS (N = 293, 586 ALLELES)**   **CONTROLS (N = 318, 636 ALLELES)**   **Intergroup comparison values**   **MS WOMEN (N = 203, 406 ALLELES)**   **CONTROL WOMEN (N = 221, 442 ALLELES)**   **Intergroup comparison values**   **MS MEN (N = 90, 180 ALLELES)**   **CONTROL MEN (N = 97, 194 ALLELES)**   **Intergroup comparison values**
  ------------------------- ---------------------------------------- ------------------------------------- ---------------------------------- ------------------------------------- ------------------------------------------ ---------------------------------- ---------------------------------- --------------------------------------- ----------------------------------
  rs9652490 GENOTYPE A/A                  197 (67.2%)                             222 (69.8%)                                                              139 (68.5%)                             153 (69.2%)                                                                58 (64.4%)                           69 (71.1%)                                 
  A/G                                      92 (31.4%)                             86 (27.0%)                           P = 0.197                           62 (30.5%)                               60 (27.1%)                             P = 0.170                          30 (33.3%)                           26 (26.8%)                           P = 0.651 \*
  G/G                                       4 (1.4%)                               10 (3.1%)                                                                2 (1.0%)                                 8 (3.6%)                                                                  2 (2.2%)                             2 (2.1%)                                  
  Allele A                                486 (82.9%)                             530 (83.3%)                             \--                              340 (83.7%)                             366 (82.8%)                                \--                            146 (81.1%)                           164 (84.5%)                              \--
  Allele G                                100 (17.1%)                             106 (16.7%)                         OR (95% CI)                          66 (16.3%)                               76 (17.2%)                            OR (95% CI)                         34 (18.9%)                           30 (15.5%)                           OR (95% CI)
  1.03 (0.76-1.39)                      0.94 (0.65-1.34)                       1.27 (0.74-2.18)                                                                                                                                                                                                                                              
  P = 0.853                                P = 0.715                               P = 0.380                                                                                                                                                                                                                                                 
  rs11856808 GENOTYPE C/C                 137 (46.8%)                             145 (45.6%)                                                              95 (46.8%)                              101 (45.7%)                                                                42 (46.7%)                            44 (45.4%                                 
  C/T                                     126 (43.0%)                             149 (46.9%)                          P = 0.407                           90 (44.3%)                              103 (46.6%)                             P = 0.852                          36 (40.0%)                           46 (47.4%)                            P = 0.313
  T/T                                      30 (10.2%)                              24 (7.5%)                                                                18 (8.9%)                               17 (7.7%)                                                                 12 (13.3%)                            7 (7.2%)                                  
  Allele C                                400 (68.3%)                             439 (69.0%)                             \--                              280 (69.0%)                             305 (69.0%)                                \--                            120 (66.7%)                           134 (69.1%)                              \--
  Allele T                                186 (31.7%)                             197 (31.0%)                         OR (95% CI)                          126 (31.0%)                             137 (31.0%)                            OR (95% CI)                         60 (33.3%)                           60 (30.9%)                           OR (95% CI)
                                                                                                                    1.04 (0.81-1.32)                                                                                                    1.00 (0.75-1.34)                                                                                              1.08 (0.60-1.43)
                                                                                                                       P = 0.773                                                                                                           P = 0.990                                                                                                     P = 0.725

P values correspond to 3x2 contingency tables (exact test). \* Fisher's exact test.

The distribution of rs9652490 and rs11856808 allelic and genotype frequencies were not influenced by gender (Table [2](#T2){ref-type="table"}). The distribution of the *LINGO1* rs9652490 and rs11856808 genotype and allelic frequencies did not differ between each MS phenotype and controls (Table [3](#T3){ref-type="table"}) or in the severity scores: expanded disability status scale or progression index. Haplotype analyses indicated that the commonest rs9652490-rs11856808 haplotype was AC (63.5% among patients and 69.2% among control individuals), followed by GT (19.4% and 16.6%, respectively) and AT (15.2% and 14.2%, respectively). These analyses did not reveal any differences in haplotype frequencies on comparing patients and control individuals (p \> 0.05 for all comparisons). Haplotypes did not differ when subgroups of patients were compared according to gender, age at onset, MS phenotypes or severity scores (p \> 0.05 for all comparisons).

###### 

***LINGO1*genotypes and allelic variants in patients with MS, and relation with the evolutive type of MS**

                         **RELAPSING-REMITTING MS (N = 159; 318 ALLELES)**   **Intergroup comparison values**   **SECONDARY PROGRESSIVE MS (N = 91; 182 ALLELES)**   **Intergroup comparison values**   **PRIMARY PROGRESSIVE MS (N = 43; 86 ALLELES)**   **Intergroup comparison values**   **CONTROLS (N = 318, 636 ALLELES)**
  --------------------- --------------------------------------------------- ---------------------------------- ---------------------------------------------------- ---------------------------------- ------------------------------------------------- ---------------------------------- -------------------------------------
  rs9652490 GENOTYPE                                                                                                                                                                                                                                                                        
  A/A                                       102 (64.2%)                                                                             62 (68.1%)                                                                            33 (76.7%)                                                                     222 (69.8%)
  A/G                                       56 (35.2%)                                  P = 0.055                                   26 (28.6%)                                   P =0.956                                 10 (23.3%)                                 P = 0.405                           86 (27.0%)
  G/G                                        1 (0.6%)                                                                                3 (3.3%)                                                                              0 (0.0%)                                                                       10 (3.1%)
  Allele A                                  260 (81.8%)                                    \--                                     150 (82.4%)                                     \--                                    76 (88.4%)                                    \--                              530 (83.3%)
  Allele G                                  58 (18.2%)                                 OR (95% CI)                                  32 (17.6%)                                 OR (95% CI)                                10 (11.6%)                                OR (95% CI)                          106 (16.7%)
  1.12 (0.78-1.59)                       1.07 (0.69-1.65)                            0.66 (0.33-1.31)                                                                                                                                                                                       
  P = 0.544                                  P = 0.771                                  P = 0.232                                                                                                                                                                                           
  rs11856808 GENOTYPE                                                                                                                                                                                                                                                                       
  C/C                                       67 (42.1%)                                                                              43 (47.3%)                                                                            27 (62.8%)                                                                     145 (45.6%)
  C/T                                       77 (48.4%)                                  P = 0.670                                   35 (38.5%)                                  P = 0.095                                 14 (32.6%)                                 P = 0.112                           149 (46.9%)
  T/T                                        15 (9.4%)                                                                              13 (14.3%)                                                                             2 (4.7%)                                                                       24 (7.5%)
  Allele C                                  211 (66.4%)                                    \--                                     121 (66.5%)                                     \--                                    68 (79.1%)                                    \--                              439 (69.0%)
  Allele T                                  107 (33.6%)                                OR (95% CI)                                  61 (33.5%)                                 OR (95% CI)                                18 (20.9%)                                OR (95% CI)                          197 (31.0%)
                                                                                     1.13 (0.85-1.51)                                                                        1.12 (0.79-1.60)                                                                     0.59 (0.34-1.02)                             
                                                                                        P = 0.404                                                                               P = 0.515                                                                            P = 0.056                                 

P values correspond to 3x2 contingency tables (exact test).

Discussion
==========

The possible role of LINGO1 in the pathogenesis of MS makes it reasonable to analyse the possible relationship between *LINGO1* polymorphisms and the risk of MS. In the present study, we found no significant differences in allele genotypes, or haplotypes frequencies for the rs9652490 and rs11856808 polymorphisms when comparing patients with MS and healthy control subjects. Nor were these polymorphisms related with the age at onset of MS or with the evolutive type of MS. The findings obtained, though negative, are novel and represent an incremental advance in the knowledge of the clinical implications of the *LINGO1* gene polymorphism.

Some experimental data suggest a possible role of *LINGO1* in the pathogenesis of MS: (a) Nogo-A expression has been found to be enhanced in surviving oligodendrocytes, while NgR has been found to be up-regulated in reactive astrocytes and macrophages/microglia in chronic active demyelinating lesions of MS \[[@B33]\], (b) TROY has been found to be up-regulated, whereas LINGO1 expression has been found to be reduced, in MS brains \[[@B34]\], (c) *LINGO1* knockout mice have shown earlier onset of myelination of CNS axons than the wild-type, and greater resistance to the development of myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) \[[@B35]\]; (d) Treatment with antibody antagonists against LINGO1 function induces functional recovery and increases integrity of axons in MOG-induced EAE \[[@B35]\], and promotes oligodendrocyte precursor cell differentiation and remyelination in different experimental models of demyelination and remyelination \[[@B36]\].

The *LINGO1* SNPs analyzed in this study have been studied as putative risk biomarkers for other movement disorders. A recent meta-analysis, which included 3,972 essential tremor (ET) patients and 20,714 controls for the LINGO1 rs9652490 polymorphism, and 2,076 ET patients and 18,792 controls for the rs11856808 polymorphism, concluded that the rs11856808 polymorphism was related with increased risk for both total and familial ET, whereas the rs9652490 polymorphism was related with increased risk for familial ET \[[@B21]\]. With regard to Parkinson's disease, another recent meta-analysis including 5,541 patients and 5,647 controls for the rs9652490 polymorphism and 3,276 patients and 3,371 controls for the rs11856808 polymorphism concluded that these polymorphisms could not be considered as major risk factors for susceptibility to PD \[[@B22]\].

Several SNPs have been described within the *LINGO1* gene and in the 3' flanking region (Figure [1](#F1){ref-type="fig"}). It is to be noted that most genetic association studies on *LINGO1* focused on the same SNPs which were analyzed in the present study \[[@B17]-[@B19],[@B21]-[@B24],[@B37]-[@B50]\]. Although several *LINGO1* nonsynonymous SNPs have been described, namely rs113329801, rs201732477, rs112205560, rs150289554, rs113096707, rs188738703, rs200688402, rs200463885, rs9855, rs201517725, rs184237450, rs77436810, rs193100227, rs111741384, rs202233236, rs199976207, rs199628078, rs201438433, rs140914739, rs200528664, rs111605415 and rs202223502, none of these SNPs show a minor allele frequency over 0.0005 (see the website <http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?showRare=on&chooseRs=all&go=Go&locusId=84894>). Therefore, the identification of one heterozygous individual out of 1000 individuals studied is to be expected. This precluded the analysis of these nonsynonymous SNPs as putative risk factors. Nevertheless, the two SNPs studied are linked with other SNPs within the coding region of the *LINGO1* gene. Figure [1](#F1){ref-type="fig"} show that linkage varies depending on the population studied, being low in individuals of African descent, high in individuals of Oriental descent or in related populations (of Amerindian descent), and intermediate in individuals of Caucasian descent. The Italian Tuscany population shows a higher linkage than other Caucasian individuals, probably due to genetic admixture with other Mediterranean populations. This admixture took also place in Spain. The Figure indicates that the two SNPs analyzed in this study are linked to the rest of the SNPs shown in the Figure.

The present study has some limitations. First, the size of analyzed cohorts may not be sufficient for strict conclusions about *LINGO1* role in MS. As was shown in a previous publication about the role of LINGO1 in essential tremor risk, individual studies of small number of patients gave very contradictory results \[[@B21]\]. Second, although the sample size is adequate to detect an OR as small as 1.5, a more modest association would not be detected. Third, because EDSS or progression index are not completely adequate measures of disease severity, the negative association observed in this study does not rule out a putative association with disease severity. Moreover, because the cohort study included MS patients with different degrees of severity, it is not adequate for the investigation of the influence of *LINGO1* genotypes on the disability or severity of MS (the ideal study for this purpose should include genotyping of patients with a recent diagnosis of MS with similar follow-up periods).

Conclusions
===========

In summary, taking in account the limitations of the present study, our results suggest that rs9652490 and rs11856808 genotype and allelic variants are not related with the risk for MS in Caucasian Spanish people.
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